Remus Pharmaceuticals Limited (NSE: REMUS)

Market Cap	15.15B
Revenue (ttm)	4.57B
Net Income (ttm)	299.01M
Shares Out	5.89M
EPS (ttm)	50.73
PE Ratio	50.69
Forward PE	n/a
Dividend	2.00 (0.08%)
Ex-Dividend Date	Nov 19, 2024

Volume	2,000
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	1,012.50 - 2,834.75
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Remus Pharmaceuticals

Remus Pharmaceuticals Limited engages in the marketing, trading, and distribution of pharmaceutical finished formulations and products in India and internationally. It is involved in trading of active pharmaceutical ingredient, as well as provides technical consultancy services to various distributors and contract manufacturing services. The company offers capsule, cream, eye drop, gel, infusion, inhalation, inhaler, injection, nail lacquer, nasal solution, nasal spray, nebulizer, ointment, ophthalmic, oral gel, oral solution, oral suspension, ...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 2015
• Employees: 48
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: REMUS

Financial Performance

In 2023, Remus Pharmaceuticals's revenue was 2.13 billion, an increase of 371.63% compared to the previous year's 451.32 million. Earnings were 215.37 million, an increase of 153.29%.